{
  "id": 16012853,
  "title": "Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease",
  "url": "https://urgent.news/2026/10/22/ferrer-and-prilenia-announce-authorization-for-eu-initiation-of",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T07:04:33.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/ferrer-and-prilenia-announce-authorization-for-eu-initiation-of-confirmatory-precise-hd-study-of-pridopidine-in-huntingtons-disease"
  },
  "original_language": "en",
  "account": null,
  "summary": "BARCELONA, Spain — Ferreri and Prilenia Therapeutics B.V. today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington’s disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}